IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

Impact · against what's priced in

The enrollment of the first two patients in the ChoICE study is a positive execution milestone but lacks immediate material impact on valuation. With only 0.5% of the 400-patient target enrolled, the company remains in the early stages of generating the real-world evidence required to drive FY2027 revenue growth.

ICCM+0.20

No priced-in read yet